Aussie equities: Why it’s smart to take the long-term view on M&A deals
Newspaper headlines have been full of merger and acquisition activity and associated capital raisings in recent months.
Chemist Warehouse-Sigma Healthcare. Brookfield-Origin. Newcrest-Newmont. Allkem-Livent. Woodside-Santos.
The activity is likely to continue in 2024, especially in the resources space.
Investors haven’t always been impressed with recent deals – but that doesn’t mean there isn’t opportunity, says Anthony Moran, an analyst with Pendal’s Aussie equities team.
“Markets tend to overreact, especially around M&A. That’s exacerbated at the moment with fears that the economic cycle is rolling over.
“Investors are concerned that companies are buying businesses that may have puffed up earnings or been trading on a cyclical peak.
“But if you can do the work on the acquired businesses and start to get an understanding and more informed perspective on the probability of the success of a deal, then a sell-off can be quite an attractive investment opportunity.”